サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1786514

勃起不全治療薬の世界市場

Erectile Dysfunction Drugs

出版日
ページ情報
英文 287 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.45円
勃起不全治療薬の世界市場
出版日: 2025年08月08日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 287 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

勃起不全治療薬の世界市場は2030年までに89億米ドルに達する見込み

2024年に57億米ドルと推定される勃起不全治療薬の世界市場は、2024年から2030年にかけてCAGR 7.8%で成長し、2030年には89億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるバイアグラは、CAGR7.8%を記録し、分析期間終了時には24億米ドルに達すると予想されます。シアリスセグメントの成長率は、分析期間中CAGR 7.7%と推定されます。

米国市場は15億米ドルと推定、中国はCAGR 12.1％で成長すると予測

米国の勃起不全治療薬市場は2024年に15億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに19億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは12.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.9%と7.4%と予測されています。欧州では、ドイツがCAGR 5.1%で成長すると予測されています。

世界の勃起不全治療薬市場- 主要動向と促進要因のまとめ

勃起不全治療薬の進歩は治療成績をどのように改善しているか？

勃起不全（ED）治療薬市場は、製薬会社がより効果的で、より長持ちし、副作用を軽減する治療薬を開発するにつれて急速に発展しています。シルデナフィル（バイアグラ）、タダラフィル（シアリス）、バルデナフィル（レビトラ）といった従来のホスホジエステラーゼ5型（PDE5）阻害薬は、依然として主要な治療選択肢であるが、調査により有効性が向上し、副作用の少ない改良型製剤が開発されています。口腔内崩壊錠、舌下フィルム、速効性スプレーなどの新しいドラッグデリバリー機構は、患者のコンプライアンスと利便性を向上させています。

PDE5阻害薬以外にも、一酸化窒素放出化合物、Rho-キナーゼ阻害薬、メラノコルチン受容体作動薬などの調査により、ED治療に新たな道が開かれつつあります。さらに、タダラフィルの低用量連日投与レジメンは、EDと前立腺肥大症（BPH）の治療における二重の特典があるとして人気を集めています。医薬品の技術革新が効果を最適化し、禁忌を最小化し続けるにつれて、ED治療の状況は、より患者中心の解決策へとシフトしつつあります。

再生医療はED治療の未来をどのように変えるのか？

再生医療は、ED治療におけるゲームチェンジャーとして台頭してきており、一時的な症状の緩和ではなく、長期的な解決策を提供する可能性があります。幹細胞療法、多血小板血漿（PRP）注射、衝撃波療法は、ED患者の組織再生を促進し、血流を促進し、神経機能を改善する能力について研究されています。これらの治療法は、血管機能障害や神経損傷といったEDの根本的な原因をターゲットとしており、重症例や治療抵抗性の症例に有望な結果をもたらしています。

遺伝子治療は、一酸化窒素のシグナル伝達や陰茎組織の修復に関与する遺伝子を改変することによって勃起機能を回復させることを目的とした、もうひとつの研究分野です。さらに、AIを活用した創薬の台頭により、遺伝子や代謝プロファイルに基づく個別化治療の開発が加速しています。再生・遺伝子ベースの治療法の研究が進むにつれて、ED治療は一時的な症状管理から長期的な性機能の回復へと移行していくと予想されます。

勃起不全治療薬市場の成長を促進する主な要因は？

勃起不全治療薬市場の成長は、人口の高齢化によるEDの有病率の上昇、糖尿病や心血管疾患の症例の増加、治療オプションに対する意識の高まりが原動力となっています。遠隔医療やデジタルヘルスプラットフォームの拡大により、ED治療薬がより身近なものとなり、スティグマが軽減され、患者が早期治療を求めるようになっています。

また、PDE5阻害薬のジェネリック医薬品の導入も市場浸透を拡大し、治療薬がより手頃な価格で広く入手できるようになっています。さらに、消費者が副作用の少ない代替療法を求めていることから、天然素材やハーブを使用したED治療薬の需要も増加しています。医薬品の進歩、デジタルヘルスケア、患者の嗜好が業界を形成し続ける中、ED治療薬市場は持続的な成長と革新の態勢を整えています。

セグメント

製品（バイアグラ、シアリス、レビトラ／スタキシン、ステンドラ／スペドラ、ザイデナ、その他医薬品）、投与経路（経口投与経路、注射投与経路、その他）

調査対象企業の例

  • Apricus Biosciences, Inc.
  • Aurobindo Pharma Limited
  • Bayer AG
  • Dong-A Pharmaceutical Co., Ltd.
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Futura Medical plc
  • GlaxoSmithKline plc
  • Hims & Hers Health, Inc.
  • Lupin Limited
  • Mankind Pharma
  • Petros Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Ro（Roman）
  • S.K. Chemicals Co., Ltd.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP30822

Global Erectile Dysfunction Drugs Market to Reach US$8.9 Billion by 2030

The global market for Erectile Dysfunction Drugs estimated at US$5.7 Billion in the year 2024, is expected to reach US$8.9 Billion by 2030, growing at a CAGR of 7.8% over the analysis period 2024-2030. Viagra, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the Cialis segment is estimated at 7.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 12.1% CAGR

The Erectile Dysfunction Drugs market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 12.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.9% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Erectile Dysfunction Drugs Market - Key Trends & Drivers Summarized

How Are Advancements in Erectile Dysfunction Drugs Improving Treatment Outcomes?

The erectile dysfunction (ED) drugs market is evolving rapidly as pharmaceutical companies develop more effective, longer-lasting, and side effect-reducing treatments. Traditional phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra), remain the primary treatment options, but research is leading to improved formulations with enhanced efficacy and fewer adverse effects. Novel drug delivery mechanisms, including orally disintegrating tablets, sublingual films, and fast-acting sprays, are increasing patient compliance and convenience.

Beyond PDE5 inhibitors, research into nitric oxide-releasing compounds, Rho-kinase inhibitors, and melanocortin receptor agonists is opening new avenues for ED treatment. Additionally, low-dose daily regimens of tadalafil are gaining popularity for their dual benefits in treating ED and benign prostatic hyperplasia (BPH). As pharmaceutical innovations continue to optimize effectiveness and minimize contraindications, the landscape of ED treatment is shifting towards more patient-centric solutions.

How Is Regenerative Medicine Reshaping the Future of ED Treatment?

Regenerative medicine is emerging as a game-changer in ED treatment, offering potential long-term solutions rather than temporary symptomatic relief. Stem cell therapy, platelet-rich plasma (PRP) injections, and shockwave therapy are being investigated for their ability to promote tissue regeneration, enhance blood flow, and improve nerve function in patients with ED. These therapies target the underlying causes of ED, such as vascular dysfunction and nerve damage, providing promising results for patients with severe or treatment-resistant cases.

Gene therapy is another area of exploration, aiming to restore erectile function by modifying genes involved in nitric oxide signaling and penile tissue repair. Additionally, the rise of AI-driven drug discovery is accelerating the development of personalized treatments based on genetic and metabolic profiles. As research into regenerative and gene-based therapies advances, ED treatment is expected to transition from temporary symptom management to long-term restoration of sexual function.

What Are the Key Factors Driving Growth in the Erectile Dysfunction Drugs Market?

The growth in the erectile dysfunction drugs market is driven by the rising prevalence of ED due to aging populations, increasing cases of diabetes and cardiovascular diseases, and growing awareness of treatment options. The expansion of telemedicine and digital health platforms is making ED drugs more accessible, reducing stigma, and encouraging patients to seek early treatment.

The introduction of generic versions of PDE5 inhibitors has also expanded market penetration, making treatments more affordable and widely available. Additionally, the demand for natural and herbal ED supplements is increasing, as consumers seek alternative remedies with fewer side effects. As pharmaceutical advancements, digital healthcare, and patient preferences continue to shape the industry, the ED drugs market is poised for sustained growth and innovation.

SCOPE OF STUDY:

The report analyzes the Erectile Dysfunction Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena, Other Drugs); Administration Route (Oral Administration Route, Injectable Administration Route, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Apricus Biosciences, Inc.
  • Aurobindo Pharma Limited
  • Bayer AG
  • Dong-A Pharmaceutical Co., Ltd.
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Futura Medical plc
  • GlaxoSmithKline plc
  • Hims & Hers Health, Inc.
  • Lupin Limited
  • Mankind Pharma
  • Petros Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Ro (Roman)
  • S.K. Chemicals Co., Ltd.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Erectile Dysfunction Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Aging Global Male Population Throws the Spotlight on Long-Term Demand for Erectile Dysfunction Drugs
    • Rising Awareness and Openness About Sexual Health Drives Market Penetration Across Emerging Markets
    • Expanding Digital Health Platforms and Telemedicine Services Spur Prescription Rates and Product Accessibility
    • Increasing Prevalence of Lifestyle Diseases Like Obesity and Diabetes Strengthens Business Case for ED Medications
    • Shifting Cultural Norms and Reduced Social Stigma Around ED Accelerates Demand in Traditionally Conservative Regions
    • Rising Consumer Preference for Oral Therapies Drives Adoption of PDE5 Inhibitors
    • Technological Advancements in Drug Delivery Systems Open New Avenues for Market Expansion
    • Strong Pipeline of Novel Molecules and Next-Gen ED Therapies Expands Future Addressable Market
    • Growing Focus on Male Wellness and Preventative Health Spurs Demand for ED Treatment Options
    • Increasing Incidence of Psychological and Stress-Related Erectile Dysfunction Propels Need for Integrated Treatment Solutions
    • Enhanced Access to Online Pharmacies and e-Commerce Channels Bolsters Drug Sales and Distribution Reach
    • Personalized Medicine and Genetic Profiling Strengthen the Case for Targeted ED Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Erectile Dysfunction Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Erectile Dysfunction Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Erectile Dysfunction Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Viagra by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Viagra by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Viagra by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cialis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Cialis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Cialis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Levitra / Staxyn by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Levitra / Staxyn by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Levitra / Staxyn by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Stendra / Spedra by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Stendra / Spedra by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Stendra / Spedra by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Zydena by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Zydena by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Zydena by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Oral Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Injectable Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Injectable Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Injectable Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • JAPAN
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • CHINA
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • EUROPE
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Erectile Dysfunction Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Erectile Dysfunction Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • FRANCE
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • GERMANY
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Erectile Dysfunction Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Erectile Dysfunction Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • INDIA
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Erectile Dysfunction Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Erectile Dysfunction Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Erectile Dysfunction Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Erectile Dysfunction Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030
  • AFRICA
    • Erectile Dysfunction Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Erectile Dysfunction Drugs by Product - Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Erectile Dysfunction Drugs by Product - Percentage Breakdown of Value Sales for Viagra, Cialis, Levitra / Staxyn, Stendra / Spedra, Zydena and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Erectile Dysfunction Drugs by Administration Route - Oral Administration Route, Injectable Administration Route and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Erectile Dysfunction Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectable Administration Route and Others for the Years 2015, 2025 & 2030

IV. COMPETITION